Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Nomura Holdings Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Nomura Holdings Inc trades at $9.2 (market cap $28.01B). The key difference: Nomura Holdings Inc is far larger — about 3.3× Hinge Health Inc. Class A Common Stock's market cap, and Nomura Holdings Inc pays a 3.38% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Nomura Holdings Inc for 56 Days on average.
| HNGE | NMR | |
|---|---|---|
Market Cap | $8.48B | $28.01B |
Volume | 879,799 | 686,801 |
Sector | Health | Financials |
52-Week High | $105.14 | $10.86 |
52-Week Low | $31.17 | $6.92 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $8.10B | $38.48T |
Dividend Yield | — | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Nomura Holdings (NMR) trades at $9.26, down 3.24% with bearish technical signals. The stock shows mixed earnings performance with recent misses but strong revenue growth from $1.66T in 2025. Valuation appears attractive with P/E of 11.37 and P/B of 1.16, while analyst sentiment leans cautious with 67% hold ratings. Recent Zacks coverage highlights momentum potential and hammer chart pattern formation.
Outlook remains balanced with fundamental strength in profitability margins (20.4% net income) offset by technical weakness. Investment opportunity lies in discounted valuation amid earnings growth, while risks include cash flow volatility and rising debt levels. The stock requires careful monitoring of Q3 2026 earnings results for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
